News
Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to <16 years old with ...
Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the ped ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback